Home Oxygen Therapy And Aerobic Capacity In Patients With Diffuse Interstitial Lung Disease. Cross-Sectional Study

Authors

  • Jhonatan Betancourt-Peña Facultad de Salud y Rehabilitación, Institución Universitaria Escuela Nacional del Deporte, Cali, Colombia. Facultad de Salud, Escuela de Rehabilitación Humana, Universidad del Valle, Cali, Colombia. https://orcid.org/0000-0002-7292-7628
  • Jenifer Tatiana Rodríguez-Castro Institución Universitaria Escuela Nacional del Deporte. Semillero de investigación Cardio respiratorio (SEINCAR). https://orcid.org/0000-0001-6259-3671
  • Hamilton Elias Rosero-Carvajal Institución Universitaria Escuela Nacional del Deporte Hospital Universitario del Valle Grupo de Investigación Ejercicio y Salud Cardiopulmonar, Universidad del Valle https://orcid.org/0000-0001-8831-9910

Keywords:

Interstitial lung diseases, dyspnea, oxygen, quality of life, exercise tolerance, oxygen inhalation therapy

Abstract

Introduction: Diffuse interstitial lung disease is a group of diseases that cause a disorder of aerobic capacity and quality of life; in addition, they cause a high rate of morbidity and mortality for this population. The use of home oxygen therapy greater than 15 hours a day has benefits in chronic hypoxemic patients, however, little has been compared to patients who do not receive it.

Objective: Describe the clinical characteristics, functional aerobic capacity and health-related quality of life of two groups of patients with diffuse interstitial lung disease, one with indication for home oxygen therapy and another group without indication.

Methods: A cross-sectional descriptive study included 41 patients with diffuse interstitial lung disease who signed informed consent. In both groups, demographic and clinical characteristics, anxiety/depression, health quality of life related with the Saint George questionnaire, and functional aerobic capacity with the six-minute gait test were measured. The groups were compared with the student's t-test for independent samples.

Results: The diffuse interstitial lung disease group with home oxygen therapy presented a higher percentage of smoking history (p = 0.041), a shorter distance walked in the six-minute gait test (304.1 ± 108.7 vs. 390.3 ± 95.6 p = 0.01), and a lower percentage of the predicted distance (58.37 ± 20.45 vs. 73.34 ± 22.90,    p = 0.034) compared to the diffuse interstitial lung disease group without home oxygen therapy.

Conclusions: Patients with diffuse interstitial lung disease with indication of home oxygen therapy have lower functional aerobic capacity compared to patients without indication.

Downloads

Download data is not yet available.

Author Biographies

Jhonatan Betancourt-Peña, Facultad de Salud y Rehabilitación, Institución Universitaria Escuela Nacional del Deporte, Cali, Colombia. Facultad de Salud, Escuela de Rehabilitación Humana, Universidad del Valle, Cali, Colombia.

Docente, Facultad de Salud y Rehabilitación, Institución Universitaria Escuela Nacional del Deporte, Cali, Colombia.

Docente, Facultad de Salud, Escuela de Rehabilitación Humana, Universidad del Valle, Cali, Colombia.

Investigador COLCIENCIAS

Jenifer Tatiana Rodríguez-Castro, Institución Universitaria Escuela Nacional del Deporte. Semillero de investigación Cardio respiratorio (SEINCAR).

Integrante, Institución Universitaria Escuela Nacional del Deporte. Semillero de investigación Cardio respiratorio (SEINCAR).

Hamilton Elias Rosero-Carvajal, Institución Universitaria Escuela Nacional del Deporte Hospital Universitario del Valle Grupo de Investigación Ejercicio y Salud Cardiopulmonar, Universidad del Valle

Hamilton Elías Rosero-Carvajal
Docente- Institución Universitaria Escuela Nacional del Deporte
Fisioterapeuta- Hospital Universitario del Valle
Investigador- Grupo de Investigación Ejercicio y Salud Cardiopulmonar, Universidad del Valle

References

1. Mueller-Mang C, Ringl H, Herold C. Interstitial lung diseases. Multislice CT. 2019;261–88. doi: 10.1007/174_2017_151

2. Miguel-Reyes JL, Gochicoa-Rangel L, Pérez-Padilla R, Torre-Bouscoulet L. Functional respiratory assessment in interstitial lung disease. Rev Invest Clin. 2015;67(1):5–14.

3. Rivera-Ortega P, Molina-Molina M. Interstitial lung diseases in developing countries. Ann Glob Heal. 2019;85(1):1–14. doi: 10.5334/aogh.2414

4. Holland AE. Exercise limitation in interstitial lung disease - mechanisms, significance and therapeutic options. Chron Respir Dis. 2010;7(2):101–11. doi: 10.1177/1479972309354689

5. Lindell KO. Nonpharmacological Therapies for Interstitial Lung Disease. Curr Pulmonol Rep. 2018;7(4):126–32. doi: 10.1007/s13665-018-0211-6

6. Carvajalino S, Reigada C, Johnson MJ, Dzingina M, Bajwah S. Symptom prevalence of patients with fibrotic interstitial lung disease: A systematic literature review. BMC Pulm Med. 2018;18(1):78. doi: 10.1186/s12890-018-0651-3

7. Mikolasch TA, Garthwaite HS, Porter JC. Update in diagnosis and management of interstitial lung Disease. Clin Med. 2017;17(2):146–53. doi: 10.7861/clinmedicine.17-2-146

8. Moua T, Westerly BD, Dulohery MM, Daniels CE, Ryu JH, Lim KG. Patients with fibrotic interstitial lung disease hospitalized for acute respiratory worsening: A large cohort analysis. Chest. 2016;149(5):1205–14. doi: 10.1016/j.chest.2015.12.026

9. Betancourt-Peña J, Tonguino-Rosero S, Rosero-Carvajal HE, Hurtado H. Differences of pulmonary rehabilitation in COPD patients, with and without indication for long-term domiciliary oxygen. Fisioterapia. 2018;40(4):169–77. doi: 10.1016/j.ft.2018.03.005

10. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2004;350(10):1005–12. doi: 10.1056/NEJMoa021322

11. López Alvarenga JC, Vázquez Velázquez V, Arcila Martínez D, Sierra Ovando ÁE, González Barranco J, Salin Pascual RJ. Exactitud y utilidad diagnóstica del Hospital Anxiety and Depression Scale (HAD) en una muestra de sujetos obesos mexicanos. Rev Invest Clin. 2002;54(5):403–9.

12. Betancourt-Peña J, Hurtado-Gutiérrez H. Efectos de un programa de rehabilitación pulmonar en pacientes con enfermedad pulmonar Intersticial difusa. Fisioterapia. 2015;37(6):286–92. doi: 10.1016/j.ft.2014.12.001

13. Ferrer M, Villasante C, Alonso J, Sobradillo V, Gabriel R, Vilagut G, et al. Interpretation of quality of life scores from the St George’s Respiratory Questionnaire. Eur Respir J. 2002;19(3):405–13. doi: 10.1183/09031936.02.00213202

14. Crapo RO, Casaburi R, Coates AL, Enright PL, MacIntyre NR, McKay RT, et al. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–7. doi: 10.1164/ajrccm.166.1.at1102

15. American College of Sports Medicine. ACSM’s Guidelines for Exercise Testing and Prescription. Ninth edit. Lippincott Williams & Wilkins; 2014. 456 p.

16. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824. doi: 10.1164/rccm.2009-040GL

17. Carey MA, Card JW, Voltz JW, Arbes SJ, Germolec DR, Korach KS, et al. It’s all about sex: gender, lung development and lung disease. Trends Endocrinol Metab. 2007;18(8):308–13. doi: 10.1016/j.tem.2007.08.003

18. Ministerio de salud y Protección Social. SENT 2. Morbi-Mortalidad de las enfermedades respiratorias crónicas, Colombia 2005-2013. Convenio 519 de 2015. Bogotá; 2016 Apr.

19. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63(6):549–54. doi: 10.1136/thx.2007.088070.

20. Rinaldi S, Mura M, Madill J. Obesity in Interstitial Lung Disease Patients. Can J Diabetes. 2015;39:S59–60. doi: 10.1016/j.jcjd.2015.01.224

21. Baumgartner KB, Samet JM, Stidley CA, Colby T V., Waldron JA. Cigarette smoking: A risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155(1):242–8. doi: 10.1164/ajrccm.155.1.9001319

22. Ekström M, Gustafson T, Boman K, Nilsson K, Tornling G, Murgia N, et al. Effects of smoking, gender and occupational exposure on the risk of severe pulmonary fibrosis: A population-based case-control study. BMJ Open. 2014;4(1):e004018. doi: 10.1136/bmjopen-2013-004018

23. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2014;2014(10). doi: 10.1002/14651858.CD006322.pub3

24. Lancaster LH. Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med. 2018;13(1):1–7. doi: 10.1186/s40248-018-0158-z

25. Khor YH, Renzoni EA, Visca D, McDonald CF, Goh NSL. Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns. ERJ Open Res. 2019;5(3):00118–2019. doi: 10.1183/23120541.00118-2019

26. Crockett A, Cranston JM, Antic N. Domiciliary oxygen for interstitial lung disease. Cochrane Database Syst Rev. 2001;(3):CD002883. doi: 10.1002/14651858.cd002883

27. Lim RK, Humphreys C, Morisset J, Holland AE, Johannson KA. Oxygen in patients with fibrotic interstitial lung disease: An international Delphi survey. Eur Respir J. 2019;54(2):1900421. doi: 10.1183/13993003.00421-2019

28. Caminati A, Bianchi A, Cassandro R, Rosa Mirenda M, Harari S. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med. 2009;103(1):117–23. doi: 10.1016/j.rmed.2008.07.022

29. Lederer DJ, Arcasoy SM, Wilt JS, D’Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(6):659–64. doi: 10.1164/rccm.200604-520OC

30. Wickerson L, Mathur S, Helm D, Singer L, Brooks D. Physical activity profile of lung transplant candidates with interstitial lung disease. J Cardiopulm Rehabil Prev. 2013;33(2):106–12. doi: 10.1097/HCR.0b013e3182839293

31. Johnson-Warrington V, Williams J, Bankart J, Steiner M, Morgan M, Singh S. Pulmonary rehabilitation and interstitial lung disease: Aiding the referral decision. J Cardiopulm Rehabil Prev. 2013;33(3):189–95. doi: 10.1097/HCR.0b013e31828db112

32. Akhtar AA, Ali MA, Smith RP. Depression in patients with idiopathic pulmonary fibrosis. Chron Respir Dis. 2013;10(3):127–33. doi: 10.1177/1479972313493098

33. Ryerson CJ, Arean PA, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, et al. Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology. 2012;17(3):525–32. doi: 10.1111/j.1440-1843.2011.02122.x

34. Du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: Test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011;183(9):1231–7. doi: 10.1164/rccm.201007-1179OC

35. Nathan SD, Du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir Med. 2015;109(7):914–22. doi: 10.1016/j.rmed.2015.04.008

36. Chéhère B, Bougault V, Gicquello A, Wallaert B. Cardiorespiratory Response to Different Exercise Tests in Interstitial Lung Disease. Med Sci Sport Exerc. 2016;48(12):2345–52. doi: 10.1249/MSS.0000000000001051

Downloads

Published

2022-04-27

How to Cite

1.
Betancourt-Peña J, Rodríguez-Castro JT, Rosero-Carvajal HE. Home Oxygen Therapy And Aerobic Capacity In Patients With Diffuse Interstitial Lung Disease. Cross-Sectional Study. Rev Cubana Inv Bioméd [Internet]. 2022 Apr. 27 [cited 2025 Jul. 27];41. Available from: https://revibiomedica.sld.cu/index.php/ibi/article/view/1263

Issue

Vol. 41 (2022)

Section

ARTÍCULOS ORIGINALES

License

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes: Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons (CC-BY-NC 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).

Como Revista Cubana de Investigaciones Biomédicas forma parte de la red SciELO, una vez los artículos sean aceptados para entrar al proceso editorial (revisión), estos pueden ser depositados por parte de los autores, si estan de acuerdo, en SciELO preprints, siendo actualizados por los autores al concluir el proceso de revisión y las pruebas de maquetación.